Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTW6IU)

• Drug Name: Methadone Drug Info
• Synonyms: Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Dry cough	MD12	Approved	[2]
Pain	MG30-MG3Z	Approved	[1]

• Therapeutic Class: Analgesics
• Cross-matching ID:
  PubChem CID: 4095
  ChEBI ID: CHEBI:6807
  CAS Number: CAS 76-99-3
  TTD Drug ID: DMTW6IU
  VARIDT Drug ID: DR00141
  INTEDE Drug ID: DR1039
  ACDINA Drug ID: D00406

Molecule-Related Drug Atlas

Drug(s) Targeting Opioid receptor (OPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[16]
Oxymorphone	DM65AGJ	Pain	MG30-MG3Z	Approved	[17]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[18]
Sufentanil	DMU7YEL	Analgesia	MB40.8	Approved	[19]
Naltrexone	DMUL45H	Alcohol dependence	6C40.2	Approved	[20]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[21]
Pentazocine	DM1XBHS	Pain	MG30-MG3Z	Approved	[22]
Nalmefene	DM4YWCZ	Opioid dependence	6C43.2Z	Approved	[23]
Tilidine	DMJW0VS	Pain	MG30-MG3Z	Approved	[24]
Dihydrocodeine	DMB0FWL	Allergic rhinitis	CA08.0	Phase 4	[25]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[26]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[27]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[29]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[28]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[28]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[30]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[28]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[32]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[34]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[35]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[36]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[37]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[38]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[39]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[40]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[34]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[41]

Drug(s) Metabolized By Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[42]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[43]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[44]
Levomethadyl acetate hydrochloride	DM429AE	N. A.	N. A.	Approved	[45]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[46]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[47]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[48]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[49]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[50]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[52]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[53]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[39]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[54]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[55]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[56]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[57]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[58]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[59]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[37]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[41]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[60]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[61]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[62]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[63]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[64]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[104]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[105]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[106]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[107]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[108]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[109]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[110]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[111]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[112]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[65]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[66]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[66]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[66]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[67]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[68]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[66]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[66]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[66]
Metronidazole	DMTIVEN	Abscess		Approved	[69]

Drug(s) Metabolized By Cytochrome P450 2C18 (CYP2C18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[67]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[70]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[71]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[67]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[72]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[73]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[74]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[67]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[75]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[76]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[48]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[77]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[77]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[67]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[78]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[79]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[80]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[77]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[81]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[71]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[82]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[83]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[67]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[85]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[67]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[86]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[87]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[88]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[90]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[67]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[91]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[92]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[93]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[94]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[95]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[96]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[97]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[98]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[82]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[99]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[100]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[67]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[101]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[70]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[102]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[71]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[113]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[114]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[115]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[116]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[117]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[118]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[119]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[120]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[121]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[119]

Drug(s) Affected By Toll-like receptor 4 (TLR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[122]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[123]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[126]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[127]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[128]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[129]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[130]

Drug(s) Affected By Phospholipase D2 (PLD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[131]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[14]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[131]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[132]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[133]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[133]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[134]

Drug(s) Affected By Prolactin (PRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[135]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[136]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[137]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[138]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[122]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[139]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[140]
Aripiprazole	DM3NUMH	Bipolar I disorder		Approved	[141]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[142]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[143]

Drug(s) Affected By Insulin (INS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[144]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[122]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[145]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[146]
Fructose	DM43AN2	Vomiting	MD90	Approved	[147]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[148]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[149]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[150]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[151]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[152]

Drug(s) Affected By Interleukin-4 (IL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[153]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[154]
Tolnaftate	DM28MU7	Dermatophytosis	1F28.2	Approved	[155]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[156]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[157]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[158]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[159]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[122]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[160]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[161]

Drug(s) Affected By Alpha-1-acid glycoprotein 2 (ORM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[9]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[163]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[164]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[9]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[9]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[131]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[131]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[165]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[129]

Drug(s) Affected By NF-kappa-B inhibitor alpha (NFKBIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fructose	DM43AN2	Vomiting	MD90	Approved	[166]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[167]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[168]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[169]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[170]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[171]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[172]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[173]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[174]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[175]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[176]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[177]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[178]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[179]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[180]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[181]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[182]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[184]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[185]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[176]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[186]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[187]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[188]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[175]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[166]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[168]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[178]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[179]

Drug(s) Affected By Leptin (LEP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[189]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[190]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[191]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[192]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[193]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[189]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[189]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[194]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[195]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[196]

Drug(s) Affected By Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[166]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[154]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[156]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[197]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[198]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[199]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[200]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[201]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[14]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[202]

Drug(s) Affected By Cytochrome c (CYCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[168]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[203]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[204]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[205]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[206]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[207]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[122]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[162]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[208]
Pefloxacin	DM49IGF	Gonococcal urethritis	1A70.0Y	Approved	[209]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[210]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[167]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[211]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[212]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[213]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[205]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[214]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[215]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[216]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[217]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[218]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[219]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[220]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[221]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[221]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[222]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[223]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[224]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[225]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[221]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor (OPR)	TTN4QDT	NOUNIPROTAC	Agonist	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[5]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[5]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[5]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[6]
Aromatase (CYP19A1)	DEQX145	CP19A_HUMAN	Substrate	[7]
Cytochrome P450 2B6 (CYP2B6) Main DME	DEPKLMQ	CP2B6_HUMAN	Substrate	[5]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[5]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[5]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1-acid glycoprotein 2 (ORM2)	OTRJGZP8	A1AG2_HUMAN	Protein Interaction/Cellular Processes	[9]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Protein Interaction/Cellular Processes	[10]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[11]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Protein Interaction/Cellular Processes	[10]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Gene/Protein Processing	[12]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Protein Interaction/Cellular Processes	[13]
Interleukin-2 (IL2)	OTGI4NSA	IL2_HUMAN	Gene/Protein Processing	[14]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[14]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Gene/Protein Processing	[15]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[14]

References

• [1] Methadone FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
• [4] In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80(4):304-11.
• [5] Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
• [6] Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9.
• [7] Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
• [8] Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
• [9] Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
• [10] Methadone induces necrotic-like cell death in SH-SY5Y cells by an impairment of mitochondrial ATP synthesis. Biochim Biophys Acta. 2010 Nov;1802(11):1036-47. doi: 10.1016/j.bbadis.2010.07.024. Epub 2010 Aug 3.
• [11] Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models. Toxicol In Vitro. 2010 Mar;24(2):630-7. doi: 10.1016/j.tiv.2009.10.005. Epub 2009 Oct 17.
• [12] Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos. 2006 Jul;34(7):1167-74.
• [13] Psychoneuroendocrine effects of methadone maintenance. Psychoneuroendocrinology. 1989;14(5):371-91. doi: 10.1016/0306-4530(89)90007-3.
• [14] opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes. J Neuroimmunol. 2013 Oct 15;263(1-2):35-42. doi: 10.1016/j.jneuroim.2013.07.012. Epub 2013 Jul 25.
• [15] Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment. Physiol Res. 2005;54(1):73-78. doi: 10.33549/physiolres.930568.
• [16] The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
• [18] Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
• [19] mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
• [20] An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
• [21] Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
• [22] Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
• [23] Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
• [24] Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
• [25] Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
• [26] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [27] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [28] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [29] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [30] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [31] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [32] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [33] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [34] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [35] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [36] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [37] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [38] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [39] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [40] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [41] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [42] Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975 Nov 15;2(7942):943-6.
• [43] Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
• [44] Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes. Differences from human placental aromatase. J Steroid Biochem. 1988 Jan;29(1):119-25.
• [45] N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
• [46] Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev. 2008 Mar;57(2):431-43.
• [47] Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
• [48] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [49] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [50] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [51] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [52] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [53] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [54] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [55] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [56] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [57] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [58] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [59] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [60] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [61] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [62] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [63] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [64] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [65] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [66] Drug Interactions Flockhart Table
• [67] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [68] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [69] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [70] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [71] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [72] Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
• [73] Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
• [74] CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
• [75] Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
• [76] Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
• [77] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [78] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [79] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [80] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [81] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [82] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [83] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [84] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [85] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [86] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [87] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [88] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [89] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [90] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [91] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [92] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [93] Drugs that may have potential CYP2B6 interactions.
• [94] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [95] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [96] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [97] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [98] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [99] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [100] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [101] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [102] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [103] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [104] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [105] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [106] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [107] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [108] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [109] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [110] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [111] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [112] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [113] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [114] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [115] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [116] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [117] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [118] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [119] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [120] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [121] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [122] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [123] Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
• [124] Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-B signaling pathway. Immunobiology. 2011 Mar;216(3):367-73. doi: 10.1016/j.imbio.2010.07.011. Epub 2010 Aug 19.
• [125] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [126] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [127] Mechanical stress-activated immune response genes via Sirtuin 1 expression in human periodontal ligament cells. Clin Exp Immunol. 2012 Apr;168(1):113-24. doi: 10.1111/j.1365-2249.2011.04549.x.
• [128] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [129] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [130] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [131] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [132] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [133] Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
• [134] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [135] Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
• [136] [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
• [137] Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
• [138] Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
• [139] The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
• [140] Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
• [141] The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
• [142] Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
• [143] Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
• [144] Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes. 1997 Mar;46(3):508-12. doi: 10.2337/diab.46.3.508.
• [145] A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest. 1967 Jan;46(1):86-94. doi: 10.1172/JCI105514.
• [146] Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999 Jul;34(1):83-8. doi: 10.1161/01.hyp.34.1.83.
• [147] Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):381-5. doi: 10.1046/j.1440-1681.2002.03668.x.
• [148] Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
• [149] Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-4. doi: 10.1016/j.jdiacomp.2004.05.001.
• [150] Clonidine effect on insulin secretion and lipolysis in man. Acta Diabetol Lat. 1978 May-Aug;15(3-4):192-7. doi: 10.1007/BF02581064.
• [151] Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. Am J Physiol. 1986 Sep;251(3 Pt 1):E322-7. doi: 10.1152/ajpendo.1986.251.3.E322.
• [152] Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res. 1998 Oct;30(10):642-5. doi: 10.1055/s-2007-978950.
• [153] Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells. Eur Respir J. 1999 Nov;14(5):1106-12. doi: 10.1183/09031936.99.14511069.
• [154] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [155] Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol. 2001 Dec;117(6):1635-46. doi: 10.1046/j.0022-202x.2001.01566.x.
• [156] Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999 Mar;30(3):376-82. doi: 10.1016/s0168-8278(99)80093-2.
• [157] Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood. 2001 Mar 15;97(6):1742-9. doi: 10.1182/blood.v97.6.1742.
• [158] Immune responses in autoimmune hepatitis: effect of prednisone and azathioprine treatment: case report. Int J Med Sci. 2009 Jun 30;6(4):177-83. doi: 10.7150/ijms.6.177.
• [159] Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother. 2005 Sep;56(3):502-6. doi: 10.1093/jac/dki251. Epub 2005 Jul 8.
• [160] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [161] Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al. Arthritis Rheum. 1998 Sep;41(9):1704-5. doi: 10.1002/1529-0131(199809)41:9<1704::AID-ART26>3.0.CO;2-9.
• [162] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [163] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [164] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [165] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [166] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [167] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [168] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [169] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [170] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [171] Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
• [172] Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001 Dec 21;276(51):47828-33. doi: 10.1074/jbc.M106103200. Epub 2001 Oct 8.
• [173] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [174] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [175] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [176] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [177] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [178] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [179] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [180] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [181] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [182] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [183] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [184] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [185] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [186] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [187] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [188] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [189] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [190] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [191] Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010 Apr 1;140(1):73-81. doi: 10.1016/j.ijcard.2008.11.017. Epub 2008 Dec 6.
• [192] [Quercetin affects leptin and its receptor in human gastric cancer MGC-803 cells and JAK-STAT pathway]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jan;28(1):12-6.
• [193] Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab. 2000 Aug;85(8):2678-84. doi: 10.1210/jcem.85.8.6733.
• [194] Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
• [195] The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
• [196] Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol. 2009 Mar 20;133(1):23-31. doi: 10.1016/j.ijcard.2007.11.058. Epub 2008 Jan 15.
• [197] Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol. 1992 Apr;87(4):465-70.
• [198] Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36. doi: 10.1016/j.ejphar.2005.10.068.
• [199] Interleukin-2-induced antinociception in morphine-insensitive rats. Acta Pharmacol Sin. 2002 Nov;23(11):981-4.
• [200] Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. BMC Immunol. 2006 Nov 21;7:27. doi: 10.1186/1471-2172-7-27.
• [201] Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002 Dec;133(1-2):124-31. doi: 10.1016/s0165-5728(02)00370-3.
• [202] 1,25-Dihydroxyvitamin D3-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation. Cancer Res. 1986 Nov;46(11):5827-31.
• [203] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [204] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [205] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [206] K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
• [207] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [208] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [209] Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.
• [210] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [211] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [212] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [213] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [214] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [215] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [216] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [217] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [218] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [219] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [220] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [221] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [222] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [223] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [224] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [225] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.